TABLE 3.
Rates of voriconazole resistance in vitro among species and clinical specimens
| Species and source of clinical specimen | No. of strains | No. (%) of strains with indicated MIC (mg/liter) |
|
|---|---|---|---|
| >0.12c | >1d | ||
| Candida albicans | |||
| Deep sitesa | 1,116 | 27 (2.4) | 15 (1.3) |
| Oropharynx | 300 | 61 (20.3) | 13 (4.3) |
| Otherb | 482 | 8 (1.6) | 1 (0.2) |
| Total | 1,898 | 96 (5) | 29 (1.5) |
| Candida parapsilosis | |||
| Deep sitesa | 726 | 8 (1.1) | 1 (0.1) |
| Oropharynx | 13 | 1 (7.7) | 0 (0) |
| Otherb | 186 | 3 (1.6) | 1 (0.5) |
| Total | 925 | 12 (1.2) | 2 (0.2) |
| Candida tropicalis | |||
| Deep sitesa | 376 | 39 (10.4) | 21 (5.6) |
| Oropharynx | 20 | 2 (10) | 1 (5) |
| Otherb | 84 | 12 (14.3) | 5 (5.9) |
| Total | 480 | 53 (11) | 27 (5.6) |
| Candida glabrata | |||
| Deep sitesa | 431 | 172 (39.9) | 37 (8.6) |
| Oropharynx | 36 | 20 (55.5) | 7 (19.4) |
| Otherb | 215 | 91 (42.3) | 17 (7.9) |
| Total | 682 | 283 (41.2) | 61 (8.9) |
| Candida krusei | |||
| Deep sitesa | 157 | 134 (85.3) | 3 (1.9) |
| Oropharynx | 33 | 28 (84.8) | 2 (6.1) |
| Otherb | 51 | 43 (84.3) | 1 (1.9) |
| Total | 241 | 205 (85) | 6 (2.5) |
a
Deep sites included blood cultures, tissue biopsy specimens, and internal body fluids.
b
Other sources included vaginal exudates and skin, hair, and nail samples.
c
The voriconazole clinical breakpoint and ECOFF value defined by EUCAST for C. albicans, C. parapsilosis, and C. tropicalis.
d
The voriconazole ECOFF value defined by EUCAST for C. glabrata and C. krusei.